Home  /  Resource Library  /  Distinct immunologic kinetics and cytomegalovirus reactivation incidence with rituximab versus obinutuzumab-bendamustine in follicular lymphoma: a single-center case series study

Distinct immunologic kinetics and cytomegalovirus reactivation incidence with rituximab versus obinutuzumab-bendamustine in follicular lymphoma: a single-center case series study

Study investigated cytomegalovirus reactivation in patients with follicular lymphoma treated with rituximab or obinutuzumab.